Zobrazeno 1 - 10 of 19 pro vyhledávání: '"John Kastelein"'
1
Akademický článek
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Autor: Maciej Banach, Stanisław Surma, Zeljko Reiner, Niki Katsiki, Peter E. Penson, Zlatko Fras, Amirhossein Sahebkar, Francesco Paneni, Manfredi Rizzo, John Kastelein
Publikováno v: Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-10 (2022)
Abstract Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physici
Externí odkaz: https://doaj.org/article/464fdc478f9b4d84b59c7b59037f54e3
Zobrazit plný text záznamu
2
Akademický článek
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Autor: Ulf Landmesser, Børge G Nordestgaard, Leslie Cho, Niels Eske Bruun, Sotirios Tsimikas, Stephen J Nicholls, A Michael Lincoff, Steven E Nissen, Eran Leitersdorf, Kathy Wolski, John Kastelein, Michael Blaha, Ryuichi Morishita, Junhao Liu, Brian Manning, Plamen Kozlovski, Anastasia Lesogor, Tom Thuren, Taro Shibasaki, Florin Matei, Fábio Serra Silveira, Andreas Meunch, Aysha Bada, Vinod Vijan
Publikováno v: Open Heart, Vol 9, Iss 2 (2022)
Objective Lipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global
Externí odkaz: https://doaj.org/article/69a4df2faa554bac9af4585ef3cef707
Zobrazit plný text záznamu
3
Akademický článek
Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world
Autor: Anselm K. Gitt, Dominik Lautsch, Jean Ferrieres, John Kastelein, Heinz Drexel, Martin Horack, Philippe Brudi, Brecht Vanneste, Peter Bramlage, Francois Chazelle, Vasilisa Sazonov, Baishali Ambegaonkar
Publikováno v: Data in Brief, Vol 9, Iss C, Pp 616-620 (2016)
Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, high-risk, and non-high-risk for cardio
Externí odkaz: https://doaj.org/article/15c7ec6df7d444fda1e1b84ab7f4acb9
Zobrazit plný text záznamu
8
Abstract 23082: Gemcabene Add-On Therapy to High- and Moderate-Intensity Statin Stratums in Hypercholesterolemic Subjects (ROYAL-1, a Phase 2b Study)
Autor: Juan Frias, John Kastelein, Rebecca Bakker-Arkema, Liz Masson, Lee Golden, Charles Bisgaier, Evan Stein
Publikováno v: Circulation. 136
Introduction: Recent large cardiovascular event outcome trials with ezetimibe and a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor added to statins demonstrated benefit from additional LDL-C reduction. Despite availability of approve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a384814dffeaf0aca52464bdbd652091
https://doi.org/10.1161/circ.136.suppl_1.23082
Zobrazit plný text záznamu
9
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Autor: Paul M Ridker, Jean G MacFadyen, Brendan M Everett, Peter Libby, Tom Thuren, Robert J Glynn, John Kastelein, Wolfgang Koenig, Jacques Genest, Alberto Lorenzatti, John Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Fonseca, Jose Nicolau, Nina Gotcheva, Huo Yong, Miguel Urina-Triana, Davor Milicic, Renata Cifkova, Riina Vettus, Stephan D Anker, Athanasios J Manolis, Fernando Wyss, Tamas Forster, Axel Sigurdsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birute Petrauskiene, Leon Salvador, Jan Hein Cornel, Tor Ole Klemsdal, Felix Medina, Andrzej Budaj, Luminita Vida-Simiti, Zhanna Kobalava, Petar Otasevic, Daniel Pella, Mitja Lainscak, Ki-Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Donath, Juey-Jen Hwang, Hakan Kultursay, Marcus Flather, Christie Ballantyne, Seth Bilazarian, William Chang, Cara East, Les Forgosh, Barry Harris, Monica Ligueros
Publikováno v: Lancet, 391(10118), 319-328. Elsevier Limited
Background: Canakinumab, a monoclonal antibody targeting interleukin-1β reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35120ce9f670c69048ad08ff07b1c5c4
https://pubmed.ncbi.nlm.nih.gov/29188815
Zobrazit plný text záznamu
10
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Autor: Paul M Ridker, Jean G MacFadyen, Tom Thuren, Brendan M Everett, Peter Libby, Robert J Glynn, Paul Ridker, Alberto Lorenzatti, Henry Krum, John Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Fonseca, Jose Nicolau, Nina Gotcheva, Jacques Genest, Huo Yong, Miguel Urina-Triana, Davor Milicic, Renata Cifkova, Riina Vettus, Wolfgang Koenig, Stephan D Anker, Athanasios J Manolis, Fernando Wyss, Tamas Forster, Axel Sigurdsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birute Petrauskiene, Leon Salvador, John Kastelein, Jan Hein Cornel, Tor Ole Klemsdal, Felix Medina, Andrzej Budaj, Luminita Vida-Simiti, Zhanna Kobalava, Petar Otasevic, Daniel Pella, Mitja Lainscak, Ki-Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Donath, Juey-Jen Hwang, Hakan Kultursay, Marcus Flather, Christie Ballantyne, Seth Bilazarian, William Chang, Cara East, Brendan Everett, Les Forgosh, Robert Glynn, Barry Harris, Monica Ligueros, Erin Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Danik, Graham McMahon, Bradley Maron, MingMing Ning, Benjamin Olenchock, Reena Pande, Todd Perlstein, Aruna Pradhan, Natalia Rost, Aneesh Singhal, Viviany Taqueti, Nancy Wei, Howard Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie Gralow, Tina Mayer, Hope Rugo, Vance Fowler, Ajit P Limaye, Sara Cosgrove, Donald Levine, Renato Lopes, John Scott, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, Sheryl Manfreda, Tom Ponce, Jane Kam, Ravinder Saini, Kehur Banker, Thomas Salko, Panjat Nandy, Ronda Tawfik, Greg O'Neil, Shobha Manne, Pravin Jirvankar, Shankar Lal, Deepak Nema, Jaison Jose, Rory Collins, Kent Bailey, Roger Blumenthal, Helen Colhoun, Bernard Gersh
Publikováno v: Lancet (London, England). 390(10105)
Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes S
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::812cc417728b9562fe3fc374d1a8746d
https://pubmed.ncbi.nlm.nih.gov/30370085
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje